Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Dexpramipexole targets eosinophilic inflammation Knopp Biosciences’ investigational, first-in-class drug, dexpramipexole, holds promise for patients with asthma and eosinophil-associated diseases.

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its Phase II trial. The strategic combination of IL-33 inhibitors with ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...

From cancer immunotherapy to diabetes and weight loss breakthroughs, 2025’s top-selling drugs highlight how pharmaceutical ...

Food allergies affect up to 10% of the population in the USA and have been increasing in prevalence over the last 2–3 ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...